Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

10.69
-0.2100-1.93%
Post-market: 10.690.00000.00%19:43 EDT
Volume:748.54K
Turnover:8.13M
Market Cap:931.71M
PE:-5.02
High:11.24
Open:10.90
Low:10.65
Close:10.90
52wk High:36.26
52wk Low:5.36
Shares:87.16M
Float Shares:71.89M
Volume Ratio:0.64
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1289
EPS(LYR):-1.8700
ROE:-52.74%
ROA:-31.82%
PB:2.16
PE(LYR):-5.72

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 09

LifeSci Capital Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Jun 06

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)

TIPRANKS
·
Jun 06

UBS Remains a Buy on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Jun 05

Olema grants 176,150 inducement stock options at $12.71 per share

Reuters
·
Jun 03

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

Olema Pharmaceuticals (OLMA) Gets a Buy from Guggenheim

TIPRANKS
·
Jun 01

Olema Pharmaceuticals: Buy Rating Reiterated as Pipeline Progress Supports Attractive Risk/Reward with Unchanged $62 Price Target

TIPRANKS
·
Jun 01

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Olema Pharmaceuticals (OLMA) and CG Oncology, Inc. (CGON)

TIPRANKS
·
May 26

Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy

MT Newswires Live
·
May 26

BUZZ-Olema Pharma climbs on collaboration agreement with Bayer

Reuters
·
May 26

Olema, Bayer launch OP-3136 prostate cancer collaboration

TIPRANKS
·
May 26

Olema, Bayer partner to test OP-3136 with Nubeqa in metastatic prostate cancer trial

Reuters
·
May 26

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement With Bayer to Evaluate Op-3136 in Combination With Nubeqa® (Darolutamide) in Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
May 26

Olema Pharmaceuticals Inc - Study to Evaluate Op-3,136 and Darolutamide in 36 Patients, Initiation Expected in H2 2026

THOMSON REUTERS
·
May 26

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
May 22

Olema Highlights Encouraging OP-3136 Phase 1 Oncology Results

TIPRANKS
·
May 22

Olema reports initial Phase 1 data for OP-3136 KAT6 inhibitor in solid tumors

Reuters
·
May 22

Olema Oncology Announces Encouraging Initial Clinical Data From the Phase 1 Study of Op-3136, a Kat6 Inhibitor, at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 22

J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
May 19